Clade Therapeutics has successfully acquired Gadeta B.V., a cell therapy company specializing in innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies for cancer. This acquisition bolsters Clade’s stem cell-based medicine capabilities with Gadeta’s preclinical cell therapy programs and g/d TCR targeting technology. The integration aims to enhance the development of scalable and consistent off-the-shelf cell therapies for cancer patients. Gadeta becomes a wholly owned subsidiary of Clade in this strategic move.
Clade Therapeutics (“Clade”), a biopharmaceutical company focused on discovering and delivering engineerable, off-the-shelf, scalable, and consistent stem cell-based medicines, today announced that it has completed the acquisition of Gadeta B.V. (“Gadeta”), a cell therapy company developing innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies for cancer patients.
Gadeta is an international R&D company, focused on innovative immunotherapies for cancer. The company developed a proprietary platform to engineer novel g/d TCRs that possess broad tumor targeting capabilities. These g/d TCRs recognize unique patterns or targets on the surface of cancer cells that signal that they are diseased, thereby specifically targeting cancer cells and sparing healthy cells.
The acquisition will provide Clade with preclinical cell therapy programs, g/d TCR discovery engine and a suite of cell enhancement to improve anti-tumor activity of cell therapies. The integration of Gadeta’s g/d TCR targeting technology is complementary to Clade’s cellular platform technology and will enhance the development of engineerable, off-the-shelf, scalable, and consistent stem-cell based medicines.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Under the terms of the acquisition agreement, Clade has acquired all outstanding shares of Gadeta, making it a wholly owned subsidiary of Clade. Gadeta shareholders will receive upfront and downstream economics.
“Clade is at the forefront of broadening the impact of cell therapy by establishing a more robust cellular platform with stem-cell derived immune cells,” said Chad Cowan, Ph.D., Chief Executive Officer of Clade Therapeutics. “Our technology platform consists of both a ‘Cell Foundry’ that enables the generation of adult immune cells including both CD8+ and CD4+ T Cells, as well as a ‘Cloaking Engine’ that ensures best-in-class and tuned protection from both the cellular and humoral wings of a host’s immune system. The acquisition of Gadeta represents a strategic move to integrate a third element to our platform: ‘Universal Targeting’. This integration seamlessly complements Clade’s existing platform and commitment to developing engineerable, off-the-shelf, scalable, and consistent cell medicines.”
Jim Glasheen, Ph.D., President and Chief Business Offer of Clade Therapeutics added, “Gadeta has generated compelling in-vitro and in-vivo data over the last few years with its lead gamma/delta (g/d) TCRs in solid tumor indications and we’re excited to integrate this novel targeting into Clade’s solid tumor programs. Clade’s pipeline programs are focused on replicating the benefits of the autologous cell therapy products, while addressing their profound limitations – inconsistent quality, challenging patient logistics, and lack of scalability. This acquisition reaffirms our belief that Clade’s engineerable platform provides the right ‘chassis’ for integrating compelling innovations coming out of the autologous cell therapy ecosystem.”
Marcel Zwaal, Chief Executive Officer of Gadeta said, “Today, we are pleased to announce a significant milestone in the journey of Gadeta. Our pipeline of novel, distinctive g/d TCRs has the potential to make a significant impact to the lives of patients with solid tumors, and this strategic transaction with Clade Therapeutics represents a major step towards bringing our novel g/d TCRs to the clinic in an off-the-shelf platform.”
Source: Bio Space